Antiretroviral therapy (ART) inhibits HIV replication but is not curative. During ART, the
integrated HIV genome persists indefinitely within CD4+ T cells and perhaps other cells …

Antiretroviral therapy can effectively block HIV-1 replication and prevent or reverse
immunodeficiency in HIV-1-infected individuals. However, viral replication resumes within …

HIV-1 persists in a latent reservoir in resting CD4+ T cells despite antiretroviral therapy
(ART). The reservoir decays slowly over the first 7 years of ART (t 1/2= 44 months). However …

A stable latent reservoir for HIV-1 in resting CD4+ T cells is the principal barrier to a cure,–.
Curative strategies that target the reservoir are being tested, and require accurate, scalable …

Background Antiretroviral therapy (ART) halts HIV-1 replication, decreasing viremia to below
the detection limit of clinical assays. However, some individuals experience persistent …

Understanding the drivers and markers of clonally expanding HIV-1-infected CD4+ T cells is
essential for HIV-1 eradication. We used single-cell ECCITE-seq, which captures surface …

Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …

Clonal expansion of infected CD4+ T cells is a major mechanism of HIV-1 persistence and a
barrier to achieving a cure. Potential causes are homeostatic proliferation, effects of HIV-1 …

Combination anti-retroviral therapy (ART) has revolutionized the treatment and prevention of
HIV-1 infection. Taken daily, ART prevents and suppresses the infection. However, ART …

BACKGROUND The relative stabilities of the intact and defective HIV genomes over time
during effective antiretroviral therapy (ART) have not been fully characterized. METHODS …